GBT Announces Participation in Upcoming Investor Conferences
May 05 2022 - 4:05PM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will participate in fireside chats at the
following investor conferences:
- Bank of America Securities 2022 Healthcare Conference in Las
Vegas, NV on Wednesday, May 11, at 2:40 p.m. P.T.; and
- RBC Capital Markets 2022 Global Healthcare Conference in New
York, NY on Wednesday, May 18, at 9:00 a.m. E.T.
The fireside chats will be webcast live from GBT’s website at
www.gbt.com in the Investors section. Replays of the webcasts will
be archived and available for one month following each event.
About Global Blood Therapeutics Global Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to the
discovery, development and delivery of life-changing treatments
that provide hope to underserved patient communities, starting with
sickle cell disease (SCD). Founded in 2011, GBT is delivering on
its goal to transform the treatment and care of SCD, a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor), the first FDA-approved medicine that directly
inhibits sickle hemoglobin (HbS) polymerization, the root cause of
red blood cell sickling in SCD. GBT is also advancing its pipeline
program in SCD with inclacumab, a P-selectin inhibitor in Phase 3
development to address pain crises associated with the disease, and
GBT021601 (GBT601), the company’s next generation HbS
polymerization inhibitor. In addition, GBT’s drug discovery teams
are working on new targets to develop the next generation of
treatments for SCD. To learn more, please visit www.gbt.com and
follow the company on Twitter @GBT_news.
Contact:Steven Immergut
(media)650-410-3258simmergut@gbt.com
Courtney
Roberts (investors)650-351-7881croberts@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Apr 2023 to Apr 2024